The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).
Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.
What is the best approach for treating Alzheimer's disease? Aducanumab is an amyloid beta-directed monoclonal antibody that targets the aggregated forms of amyloid beta found in the brains of people with Alzheimer's disease. In May, Dr. Niklas Mattsson-Carlgren and Dr. Ruben Smith entertained young MultiParkers by debating the pros and cons of using it.
Last summer, Aducanumab was approved by the FDA as a treatment for Alzheimer's disease. The young MultiParker's working group arranged a scientific debate where Dr. Niklas Mattsson-Carlgren and Dr. Ruben Smith, two of MultiPark's senior researchers, discussed the topic.
Watch the recorded version of the debate below.
Niklas Mattsson-Carlgren
Senior Lecturer
niklas [dot] mattsson-carlgren [at] med [dot] lu [dot] se (niklas[dot]mattsson-carlgren[at]med[dot]lu[dot]se)
Link to Niklas Mattsson-Carlgren's profile in the LU Research Portal
Twitter: @NiklasMattsson4
Ruben Smith
Physician and Associate Professor in Neurology
ruben [dot] smith [at] med [dot] lu [dot] se (ruben[dot]smith[at]med[dot]lu[dot]se)
Link to Ruben Smith in Lund University research portal
Twitter:@ErikRubenSmith
